Stockscreener 앱 받기
3.79
0.26%
-0.010
전일 마감가:
$3.80
열려 있는:
$3.89
하루 거래량:
2,931
Relative Volume:
1.02
시가총액:
$153.02M
수익:
$7.80M
순이익/손실:
$-69.02M
주가수익비율:
-1.77
EPS:
-2.1413
순현금흐름:
$-66.61M
1주 성능:
+1.07%
1개월 성능:
+1.88%
6개월 성능:
-2.00%
1년 성능:
-20.21%
1일 변동 폭
$3.7493
$3.91
1주일 범위
$3.68
$4.00
52주 변동 폭
$3.36
$7.60
Molecular Partners Ag Adr Stock (MOLN) Company Profile
MOLN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
3.79 | 142.09M | 7.80M | -69.02M | -66.61M | -2.1413 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-08-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-08-29 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2022-04-27 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-12 | 재개 | SVB Leerink | Outperform |
모두보기
Molecular Partners Ag Adr 주식(MOLN)의 최신 뉴스
Molecular Partners (NASDAQ:MOLN) Stock Price Down 2.1% – Here’s What Happened - Defense World
Molecular Partners (NASDAQ:MOLN) Trading 1.5% HigherHere's What Happened - MarketBeat
Molecular Partners (NASDAQ:MOLN) Price Target Cut to $4.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Leerink Partnrs Has Bullish Estimate for MOLN Q3 Earnings - MarketBeat
Leerink Partnrs Issues Positive Outlook for MOLN Earnings - Defense World
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners Ag shares rise 3.64% intraday after Voyager Therapeutics expands Alzheimer's disease franchise. - AInvest
Molecular Partners (NASDAQ:MOLN) Stock Price Down 3.4% – Should You Sell? - Defense World
Molecular Partners and Orano Med Present Promising Preclinical Data on MP0726, a Radio-DARPin Candidate for Ovarian Cancer Treatment - AInvest
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 - GlobeNewswire Inc.
Molecular Partners shares rise 1.93% after-hours after presenting positive data from ongoing Phase 1/2A trial. - AInvest
Molecular Partners Cuts 40 Jobs, Extends Cash Reach to 2028 - AInvest
Molecular Partners Ag shares rise 6.71% intraday after MIT and Recursion release Boltz-2 AI model. - AInvest
US NYSE/NASD Stock Directory - Minichart
Walmart, Deere, Applied Materials set to report earnings Thursday By Investing.com - Investing.com Nigeria
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com
Ziff Davis Inc (NASDAQ:ZD) Shares Jumped 1.54% In A Week. Can It Continue Rising? - Marketing Sentinel
Molecular Partners' AACR 2025 Breakthroughs: Radio-DARPins and Smart T Cell Engagers Ignite Oncology Potential - AInvest
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com
Molecular Partners reports 2024 annual results - Investing.com
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - Novartis
Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 - Novartis
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 - Novartis
Conference Calls and Individual Investors - MarketBeat
RocheDoing now what patients need next - Roche
Molecular Partners Ag Adr (MOLN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
자본화:
|
볼륨(24시간):